Printer Friendly

ImmusanT completes phase 1b clinical trial of Nexvax2.

M2 EQUITYBITES-February 24, 2017-ImmusanT completes phase 1b clinical trial of Nexvax2


ImmusanT, a clinical-stage company developing Nexvax2, has completed a phase 1b clinical trial assessing the safety and tolerability of Nexvax2 in celiac disease, it was reported yesterday.

The trial met its objectives and identified a Phase two dose regimen.

Nexvax2 is an epitope-specific immuno-therapy that consists of three immunodominant peptides, designed to protect against gluten exposure. The study was a randomised, double-blind, placebo-controlled, dose titration trial to assess the safety and tolerability of gradual dose escalation before increased maintenance doses of Nexvax2 in patients with celiac disease. The study enrolled 38 patients with celiac disease who were stratified by HLA-DQ2.5 genotype and randomly assigned to one of three cohorts. All cohorts were then randomised to escalating doses of intradermally-administered Nexvax2 or placebo followed by maintenance doses higher than those earlier tested for a period of 46 or 60 days.

The results of this clinical trial support a dosing regimen for a planned Phase two clinical trial of Nexvax2 in patients with celiac disease.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 24, 2017
Previous Article:PMV Pharmaceuticals completes USD74m Series B financing round.
Next Article:MedAvante names new vice president of research and development.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters